We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

6 hedge funds and large institutions have $1.08M invested in ProShares UltraShort NASDAQ Biotechnology in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more capital invested

Capital invested by funds: $858K → $1.08M (+$221K)

6.84% more ownership

Funds ownership: 22.81% → 29.65% (+6.8%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

14% less funds holding

Funds holding: 7 → 6 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$454K
2
Morgan Stanley
Morgan Stanley
New York
+$32

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$255K
2
TRCT
Tower Research Capital (TRC)
New York
-$163K
3
PIS
POM Investment Strategies
North Carolina
-$75

BIS Hedge Fund Activity: Q4 2024 in Review

6 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2024, worth a combined $1.08M — up 26% from $858K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of BIS and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was Jane Street, adding an estimated $454K. The largest seller was Susquehanna International Group, cutting an estimated $255K.

  • 6 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2024, down from 7 in Q3 2024.
  • Funds reported $1.08M of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2024, up 26% quarter-over-quarter.
  • 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2024 and 1 closed out, a net change of -1 holder.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2024 was Jane Street, an estimated $454K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2024 was Susquehanna International Group, an estimated $255K sold.

Based on aggregated 13F filings for Q4 2024.